Research of Zoledronic Acid and Aromatase Inhibitors as Adjuvant Therapy to Breast Cancer
Status:
Unknown status
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
Select patients of primary breast cancer whose hormone receptor is positive and accepted
postoperative adjuvant aromatase inhibitors for endocrine treatment.Treat them with
zoledronic acid 4mg intravenous infusion every six months until the end of the aromatase
treatment. Assess the disease-free survival; overall survival; combination of security, as
well as the situation of bone loss.